- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00132028
Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma
A Phase II Trial of Suberoylanilide Hydroxamic Acid (NSC-701852) for Recurrent or Primary Refractory Hodgkin's Lymphoma
Studie Overzicht
Toestand
Conditie
- Terugkerend volwassen Hodgkin-lymfoom
- Lymfocytdepletie bij volwassenen Hodgkin-lymfoom
- Volwassen lymfocyt overheersend Hodgkin-lymfoom
- Volwassen Hodgkin-lymfoom met gemengde cellulairheid
- Volwassen nodulaire sclerose Hodgkin-lymfoom
- Volwassen nodulair lymfocyt overheersend Hodgkin-lymfoom
- Adult Favorable Prognosis Hodgkin Lymphoma
- Adult Unfavorable Prognosis Hodgkin Lymphoma
Interventie / Behandeling
Gedetailleerde beschrijving
PRIMARY OBJECTIVES:
I. To evaluate the response probability (complete, complete unconfirmed, and partial) in patients with relapsed or refractory Hodgkin's lymphoma.
II. To estimate 1-year progression-free survival and overall survival in patients with relapsed or refractory Hodgkin's lymphoma treated with SAHA.
III. To assess the toxicity profile of SAHA in this patient population. IV. To perform gene expression profiling on tumor tissue before and after treatment in order to explore in a preliminary manner the association between response and specific gene expression results.
OUTLINE: This is a multicenter study.
Patients receive oral vorinostat twice daily on days 1-14. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR.
After completion of study treatment, patients are followed every 6 months for 2 years and then annually for 3 years.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Texas
-
San Antonio, Texas, Verenigde Staten, 78245
- Southwest Oncology Group (SWOG) Research Base
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed relapsed/refractory Hodgkin's lymphoma of any subtype; patients with lymphocyte predominant Hodgkin's disease (LPHD) are also eligible; clear evidence of disease progression or lack of response after the most recent therapy, including local radiation is required
- Patients must be willing to submit specimens for correlative studies
- All patients must have bidimensionally measurable disease documented within 28 days prior to registration; patients with non-measurable disease in addition to measurable disease must have all non-measurable disease assessed within 42 days prior to registration
- Patients must have unilateral bone marrow aspirate and biopsy performed within 42 days prior to registration
- Patients may have had up to five prior chemotherapy regimens
- Patients must have completed chemotherapy at least 28 days prior to registration and all toxicities must have resolved (in the opinion of the treating investigator); if last regimen included nitrosoureas or mitomycin then 42 days must have elapsed since completion of treatment; patients must not have taken valproic acid, or another histone deacetylase inhibitor, for at least 14 days prior to registration
- Patients must have completed all radiotherapy at least 14 days prior to registration and all toxicities must have resolved (in the opinion of the treating investigator)
- Patients who relapse after autologous stem cell transplant may be enrolled if they are at least three months after transplant, and after allogeneic transplant if they are at least one year posttransplant; patients should have no active related infections (i.e., fungal or viral); in the case of allogeneic transplant relapse, there should be no active acute graft versus host disease (GvHD) of any grade, and no chronic graft versus host disease other than mild skin, oral, or ocular GvHD not requiring systemic immunosuppression
- Patients must have a Zubrod performance status of 0-2
- Patients must have a CT scan of the chest/abdomen and pelvis performed within 28 days prior to registration
- Patients must not have clinical evidence of central nervous system involvement by lymphoma; any laboratory or radiographic tests performed to assess CNS involvement must be negative within 42 days of registration
- Serum LDH must be measured within 28 days prior to registration
- Absolute neutrophil count >- 1,000/mcL
- Platelet count >= 100,000/mcL
- SGOT/SGPT < 2.5 x the institutional upper limit of normal
- Serum creatinine < 2 x the institutional upper limit of normal
- Patients with a history of allergic reactions attributed to compounds of similar chemical or biological composition to SAHA are ineligible
- Patients must not have plans to receive concurrent hormonal, biological or radiation therapy; patients with potentially curative options such as salvage therapy with chemotherapy or hematopoietic stem cell transplant (HSCT) are not eligible
- Patients with a history of prior myocardial infarction, unstable angina, or stroke within 6 months are ineligible
- Patients known to be HIV-positive and receiving combination antiretroviral therapy are ineligible; in addition, HIV-positive patients not receiving combination antiretroviral therapy are also ineligible
- No prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer for which the patient has been disease-free for five years
- Pregnant or nursing women may not participate; women or men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
- Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Treatment (vorinostat)
Patients receive oral vorinostat twice daily on days 1-14.
Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR.
|
Correlatieve studies
Mondeling gegeven
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Assess Number of Patients Who Achieve Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR)
Tijdsspanne: after every 3 cycles on treatment
|
Complete Response(CR) is a complete disappearance of all disease with the exception of nodes.
No new lesions.
previously enlarged organs must have regressed and not be palpable.
Bone marrow(BM) must be negative if positive at baseline.
Normalization of markers.
CR Unconfirmed (CRU) does not qualify for CR above, due to a residual nodal mass or an indeterminate BM.
Partial Response(PR) is a 50% decrease in the SPD for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline.
No new lesions and no increase in the size of liver, spleen or other nodes.
|
after every 3 cycles on treatment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Progression-Free Survival
Tijdsspanne: after every 3 cycles on treatment, then every 6 months for 2 years, then annually for a total of 5 years.
|
Measured from date of registration to date of first observation of progression or death, or last contact date.
Progression is defined as a 50% increase in sum of products of greatest diameters (SPD) of target measurable lesions over the smallest sum observed (over baseline if no decrease during therapy) using the same techniques as baseline; appearance of a new lesion/site; unequivocal progression of non-measurable disease in the opinion of the treating physician; death due to disease without prior documentation of progression.
|
after every 3 cycles on treatment, then every 6 months for 2 years, then annually for a total of 5 years.
|
Overall Survival
Tijdsspanne: after every 3 cycles on treatment, then every 6 months for 2 years, then annually for a total of 5 years.
|
Measured from date of registration to death, or last contact date
|
after every 3 cycles on treatment, then every 6 months for 2 years, then annually for a total of 5 years.
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Mark Kirschbaum, Southwest Oncology Group
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Neoplasmata
- Lymfoproliferatieve aandoeningen
- Lymfatische ziekten
- Immunoproliferatieve aandoeningen
- Lymfoom
- Ziekte van Hodgkin
- Moleculaire mechanismen van farmacologische werking
- Enzymremmers
- Antineoplastische middelen
- Histondeacetylaseremmers
- Vorinostaat
Andere studie-ID-nummers
- NCI-2012-03071 (Register-ID: CTRP (Clinical Trial Reporting Program))
- U10CA032102 (Subsidie/contract van de Amerikaanse NIH)
- S0517 (Andere identificatie: CTEP)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op analyse van biomarkers in het laboratorium
-
Universidad Miguel Hernandez de ElcheInstitut Català de la Salut; Andaluz Health Service; Osakidetza; Servicio Madrileño... en andere medewerkersVoltooidBeroepsziektenSpanje
-
Vanderbilt University Medical Center4DMedicalVoltooid
-
Alcon ResearchVoltooid
-
McGill University Health Centre/Research Institute...Northwestern UniversityWerving
-
St. Antonius HospitalRoche DiagnosticsWervingKwaliteit van het leven | Postoperatieve complicaties | DoodNederland
-
Seoul National University HospitalOnbekendZiekte van Alzheimer | Milde cognitieve stoornisKorea, republiek van
-
University Medical Centre LjubljanaUniversity of LjubljanaActief, niet wervendHartstilstandSlovenië
-
Assiut UniversityNog niet aan het wervenSystemische lupus erythematosus
-
GAP Innovations, PBCVoltooidZiekte van Alzheimer | Milde cognitieve stoornis | Ziekte van Alzheimer, vroeg begin | Geheugenstoornissen | Geheugenstoornis | GeheugenverliesVerenigde Staten
-
Fundacio PuigvertNucleix Ltd.OnbekendUrologische neoplasmata | Urologische kankerSpanje